ProMIS Neurosciences Issues Narrated Commentary on Key Learnings from AAIC 2018

By August 7, 2018News

ProMIS Neurosciences Issues Narrated Commentary on Key Learnings from AAIC 2018

Encouraging results of recent clinical trials in Alzheimer’s disease indicate importance of selectively targeting toxic amyloid-beta oligomers


TORONTO, Ontario and CAMBRIDGE, Massachusetts – August 7, 2018– ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced it has issued a narrated commentary on key lessons from this year’s Alzheimer’s Association International Conference (AAIC).

Results of prior and current clinical trials with therapeutics targeting amyloid-beta (Aβ), including encouraging Phase 2 results of Esai/Biogen’s Ban2401 presented at AAIC, indicate that selective targeting of toxic amyloid-beta oligomers (AβO) is critical for therapeutic efficacy. The importance of neutralizing AβO toxicity represented a common theme across multiple oral presentations and posters at this year’s AAIC.

“A growing body of evidence indicates that AβO, consisting of small aggregates of two, four or twelve Aβ peptides are the toxic oligomers killing neurons in Alzheimer’s disease. Numerous scientific studies have shown that other forms of amyloid-beta, plaque, single Aβ monomers, and large Aβ aggregates are not toxic to neurons.”, stated Dr. Elliot Goldstein, ProMIS President and CEO.

“Our humanized PMN310 antibody shows unrivaled selectivity for toxic AβO derived from human AD brains, with no off-target binding to Aβ monomers or plaque. We believe the oligomer selectivity of PMN310 supports a potential best in class product profile compared to other therapeutic antibodies currently showing promising results in clinical trials.”

ProMIS’ clinical candidate, humanized PMN310, is on track to enter Phase 1 clinical testing in the second half of 2019 and will include biomarker assessment as an integral part of the study design.

ProMIS narrated commentary can be found on the ProMIS Neurosciences website by clicking on the link below:

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing antibody therapeutics targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at:

Follow us on Twitter

Like us on LinkedIn

Media inquiries for ProMIS

David Schull
Tel. 858 717-2310

Investor Relations inquiries for ProMIS

Alpine Equity Advisors
Nicholas Rigopulos, President
Tel. 617 901-0785

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783

Media Inquiries for Selexis
Mike Beyer
Sam Brown Inc.

Tel. 312-961-2502

Company Inquiries for Selexis
Robert Meister
Head, Corporate Communications

Tel.  602-953-1716

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.  This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,  believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.